We entered into a collaboration agreement with Kyinno Bio to co-develop a novel GPRC5D/BCMA/CD3 T-cell engager, MBS314.
We grant Climb Bio(NASDAQ stock code：CLYM）the exclusive rights to develop, manufacture and commercialize MIL116, an anti-APRIL (A PRoliferation-Inducing Ligand) monoclonal antibody, in the territory outside of Greater China.
